José María García-Alberca, Paz De La Guía, Esther Gris, Silvia Mendoza, María López De La Rica, José Antonio López-Trigo, Rosa López-Mongil, Teresa García-López, Raquel López-García, Teresa Rodríguez Del Rey, Javier Gay-Puente, Jesús García-Castro, Federico Casales, Xavier Morato, Mercè Boada, Gemma González-Velasco, José Manuel Marín-Carmona, Nora Inés Páez, María León, Rosario Carrillejo, Francisca Rius, Miguel Ángel Barbancho, José Pablo Lara, Encarnación Blanco-Reina
{"title":"Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease.","authors":"José María García-Alberca, Paz De La Guía, Esther Gris, Silvia Mendoza, María López De La Rica, José Antonio López-Trigo, Rosa López-Mongil, Teresa García-López, Raquel López-García, Teresa Rodríguez Del Rey, Javier Gay-Puente, Jesús García-Castro, Federico Casales, Xavier Morato, Mercè Boada, Gemma González-Velasco, José Manuel Marín-Carmona, Nora Inés Páez, María León, Rosario Carrillejo, Francisca Rius, Miguel Ángel Barbancho, José Pablo Lara, Encarnación Blanco-Reina","doi":"10.1177/13872877241292018","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adherence is critical in patients with Alzheimer's disease (AD) in order to achieve optimal benefit from therapy. However, patient compliance with the treatment remains a challenge.</p><p><strong>Objective: </strong>To evaluate, in a real-world clinical setting, caregiver preference and treatment compliance with twice-weekly versus daily transdermal rivastigmine patch in mild-to-moderate AD.</p><p><strong>Methods: </strong>92 patients who had been treated with daily rivastigmine patch for at least six months prior to switching to twice-weekly patch were evaluated. The change in therapeutic regimen was decided by the treating physician in accordance with standard practice. Caregivers' satisfaction with daily rivastigmine patch was assessed at study entry. Caregiver's preference and satisfaction with twice-weekly patch as well as patient compliance were evaluated at weeks 12 and 24 using the Alzheimer's Disease Caregiver Preference Questionnaire.</p><p><strong>Results: </strong>A significantly higher proportion of caregivers expressed a preference for the twice-weekly patch over the daily patch (<i>p</i> < 0.001), and this preference was found to be associated with ease of use (<i>p</i> < 0.001), ease of following the schedule (<i>p</i> < 0.001), and ease of compliance (<i>p</i> < 0.001). Furthermore, caregivers were more satisfied with the twice-weekly patch (<i>p</i> < 0.0001). At 24 weeks, patient compliance was significantly better with the twice-weekly patch than with the daily patch (<i>p</i> = 0.002). Caregiver burden significantly improved at the end of the treatment (<i>p</i> = 0.003). No serious adverse events were reported.</p><p><strong>Conclusions: </strong>The twice-weekly rivastigmine patch offers a convenient and straightforward dosing regimen for caregivers, with potential to enhance adherence with treatment in AD patients without causing serious adverse events.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877241292018"},"PeriodicalIF":3.4000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13872877241292018","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Adherence is critical in patients with Alzheimer's disease (AD) in order to achieve optimal benefit from therapy. However, patient compliance with the treatment remains a challenge.
Objective: To evaluate, in a real-world clinical setting, caregiver preference and treatment compliance with twice-weekly versus daily transdermal rivastigmine patch in mild-to-moderate AD.
Methods: 92 patients who had been treated with daily rivastigmine patch for at least six months prior to switching to twice-weekly patch were evaluated. The change in therapeutic regimen was decided by the treating physician in accordance with standard practice. Caregivers' satisfaction with daily rivastigmine patch was assessed at study entry. Caregiver's preference and satisfaction with twice-weekly patch as well as patient compliance were evaluated at weeks 12 and 24 using the Alzheimer's Disease Caregiver Preference Questionnaire.
Results: A significantly higher proportion of caregivers expressed a preference for the twice-weekly patch over the daily patch (p < 0.001), and this preference was found to be associated with ease of use (p < 0.001), ease of following the schedule (p < 0.001), and ease of compliance (p < 0.001). Furthermore, caregivers were more satisfied with the twice-weekly patch (p < 0.0001). At 24 weeks, patient compliance was significantly better with the twice-weekly patch than with the daily patch (p = 0.002). Caregiver burden significantly improved at the end of the treatment (p = 0.003). No serious adverse events were reported.
Conclusions: The twice-weekly rivastigmine patch offers a convenient and straightforward dosing regimen for caregivers, with potential to enhance adherence with treatment in AD patients without causing serious adverse events.
背景:阿尔茨海默病(AD)患者要想从治疗中获得最佳疗效,坚持治疗至关重要。然而,患者对治疗的依从性仍然是一个挑战:在真实世界的临床环境中,评估轻度至中度阿尔茨海默病患者护理者对每周两次与每日一次透皮利伐斯的明贴片的偏好和治疗依从性。方法:评估了92名在改用每周两次贴片前已接受每日一次利伐斯的明贴片治疗至少6个月的患者。治疗方案的改变由主治医生根据标准做法决定。研究开始时对护理人员对每日使用利伐斯的明贴片的满意度进行了评估。在第12周和第24周时,使用阿尔茨海默病护理人员偏好问卷对护理人员对每周两次贴剂的偏好和满意度以及患者的依从性进行评估:护理人员对每周两次贴片的偏好明显高于每日贴片(P P P P P = 0.002)。治疗结束后,护理人员的负担明显减轻(p = 0.003)。无严重不良事件报告:每周两次的利伐斯的明贴片为护理人员提供了一种方便、简单的给药方案,有可能提高AD患者的治疗依从性,同时不会引起严重的不良反应。
期刊介绍:
The Journal of Alzheimer''s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer''s disease. The journal publishes research reports, reviews, short communications, hypotheses, ethics reviews, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer''s disease.